Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary
- Author
- MESSERLI, Franz H (Commentator (written text))
1 ; STAESSEN, Jan A (Commentator (written text))
2 ; BASILE, Jan N10 ; CUYJET, Aloysius B11 ; DART, Richard12 ; FELICETTA, James V13 ; GRIMM, Richard H14 ; HAYWOOD, L. Julian15 ; JAFRI, Syed Z. A16 ; PROSCHAN, Michael A4 ; THADANI, Udho17 ; WHELTON, Paul K18 ; LEENEN, Frans H. H3 ; WRIGHT, Jackson T19 ; NWACHUKU, Chuke E4 ; BLACK, Henry R5 ; CUSHMAN, William C6 ; DAVIS, Barry R7 ; SIMPSON, Lara M7 ; ALDERMAN, Michael H8 ; ATLAS, Steven A9
[1] Hypertension Program Division of Cardiology, St Luke's-Roosevelt Hospital, New York, NY, United States
[2] Studies Coordinating Centre Division of Hypertension and Cardiovascular Reha bilitation, Department of Cardiovascular Disease, University of Leuven, Leuven, Belgium
[3] University of Ottawa Heart Institute, Ottawa, Ontario, Canada
[4] National Heart, Lung, and Blood Institute, Bethesda, Md, United States
[5] Rush-Presbyterian-St. Luke's Medical Center, Chicago, Ill, United States
[6] Memphis Veterans Affairs Medical Center, Tenn, United States
[7] University of Texas Health Science Center School of Public Health, Houston, United States
[8] Albert Einstein College of Medicine, Bronx, NY, United States
[9] Bronx Veterans Affairs Medical Center, NY, United States
[10] Charleston Veterans Affairs Medical Center, SC, United States
[11] New Jersey Medical School, Newark, United States
[12] Marshfield Clinic, Marshfield, Wis, United States
[13] Carl T. Hayden Veterans Affairs Medical Center, Phoenix, Ariz, United States
[14] Berman Center for Outcomes and Clinical Research, Minneapolis, Minn, United States
[15] Los Angeles County-University of Southern California Medical Center, United States
[16] Fargo Veterans Affairs Medical Center, ND, United States
[17] University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center, Oklahoma City, United States
[18] Tulane University Health Sciences Center, New Orleans, La, United States
[19] University Hospitals of Cleveland, Ohio, United States
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group, United States - Source
Hypertension (Dallas, Tex. 1979). 2006, Vol 48, Num 3 ; 359-361,374-384 [14 p.] ; ref : 52 ref
- CODEN
- HPRTDN
- ISSN
- 0194-911X
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Lippincott, Hagerstown, MD
/
Lippincott, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- angiotensin-converting enzyme antihypertensive therapy calcium channel blockers cardiovascular diseases heart failure hypertension, detection and control stroke
- Keyword (fr)
- Amlodipine Antagoniste calcium Antiangoreux Antihypertenseur Appareil circulatoire pathologie Cardiopathie coronaire Homme Hypertension artérielle Infarctus myocarde Inhibiteur angiotensin converting enzyme Lisinopril Traitement Maladie cardiovasculaire Dihydropyridine dérivé Enzyme Hydrolases Inhibiteur enzyme Myocarde pathologie Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Vaisseau sanguin pathologie
- Keyword (en)
- Amlodipine Calcium antagonist Antianginal agent Antihypertensive agent Cardiovascular disease Coronary heart disease Human Hypertension Myocardial infarction ACE inhibitor Lisinopril Treatment Cardiovascular disease Dihydropyridine derivatives Enzyme Hydrolases Enzyme inhibitor Myocardial disease Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Vascular disease
- Keyword (es)
- Amlodipino Antagonista calcio Antianginoso Antihipertensivo Aparato circulatorio patología Cardiopatía coronaria Hombre Hipertensión arterial Infarto miocardio Inhibidor angiotensin converting enzyme Lisinopril Tratamiento Cardiovascular enfermedad Dihidropiridine derivado Enzima Hydrolases Inhibidor enzima Miocardio patología Peptidases Peptidyl-dipeptidase A Peptidyl-dipeptidases Vaso sanguíneo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02F Cardiovascular system / 002B02F05 Antihypertensive agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system / 002B12B Blood and lymphatic vessels / 002B12B05 Arterial hypertension. Arterial hypotension / 002B12B05B Clinical manifestations. Epidemiology. Investigative techniques. Etiology
- Discipline
- Cardiology. Circulatory system Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18070661
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Hypertension (Dallas, Tex. 1979)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Hypertension (Dallas Tex., 1979)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:23:\"359-361,374-384 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0194-911X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MESSERLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Franz H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"STAESSEN, Jan A\";i:1;s:13:\"BASILE, Jan N\";i:2;s:18:\"CUYJET, Aloysius B\";i:3;s:13:\"DART, Richard\";i:4;s:18:\"FELICETTA, James V\";i:5;s:16:\"GRIMM, Richard H\";i:6;s:18:\"HAYWOOD, L. Julian\";i:7;s:16:\"JAFRI, Syed Z. A\";i:8;s:19:\"PROSCHAN, Michael A\";i:9;s:13:\"THADANI, Udho\";i:10;s:15:\"WHELTON, Paul K\";i:11;s:18:\"LEENEN, Frans H. H\";i:12;s:17:\"WRIGHT, Jackson T\";i:13;s:17:\"NWACHUKU, Chuke E\";i:14;s:14:\"BLACK, Henry R\";i:15;s:18:\"CUSHMAN, William C\";i:16;s:14:\"DAVIS, Barry R\";i:17;s:15:\"SIMPSON, Lara M\";i:18;s:19:\"ALDERMAN, Michael H\";i:19;s:15:\"ATLAS, Steven A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"HPRTDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Hypertension (Dallas, Tex. 1979)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Hypertension (Dallas Tex., 1979)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:23:\"359-361,374-384 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0194-911X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MESSERLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Franz H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"STAESSEN, Jan A\";i:1;s:13:\"BASILE, Jan N\";i:2;s:18:\"CUYJET, Aloysius B\";i:3;s:13:\"DART, Richard\";i:4;s:18:\"FELICETTA, James V\";i:5;s:16:\"GRIMM, Richard H\";i:6;s:18:\"HAYWOOD, L. Julian\";i:7;s:16:\"JAFRI, Syed Z. A\";i:8;s:19:\"PROSCHAN, Michael A\";i:9;s:13:\"THADANI, Udho\";i:10;s:15:\"WHELTON, Paul K\";i:11;s:18:\"LEENEN, Frans H. H\";i:12;s:17:\"WRIGHT, Jackson T\";i:13;s:17:\"NWACHUKU, Chuke E\";i:14;s:14:\"BLACK, Henry R\";i:15;s:18:\"CUSHMAN, William C\";i:16;s:14:\"DAVIS, Barry R\";i:17;s:15:\"SIMPSON, Lara M\";i:18;s:19:\"ALDERMAN, Michael H\";i:19;s:15:\"ATLAS, Steven A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"HPRTDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Hypertension (Dallas, Tex. 1979)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Hypertension (Dallas Tex., 1979)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:23:\"359-361,374-384 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0194-911X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MESSERLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Franz H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"STAESSEN, Jan A\";i:1;s:13:\"BASILE, Jan N\";i:2;s:18:\"CUYJET, Aloysius B\";i:3;s:13:\"DART, Richard\";i:4;s:18:\"FELICETTA, James V\";i:5;s:16:\"GRIMM, Richard H\";i:6;s:18:\"HAYWOOD, L. Julian\";i:7;s:16:\"JAFRI, Syed Z. A\";i:8;s:19:\"PROSCHAN, Michael A\";i:9;s:13:\"THADANI, Udho\";i:10;s:15:\"WHELTON, Paul K\";i:11;s:18:\"LEENEN, Frans H. H\";i:12;s:17:\"WRIGHT, Jackson T\";i:13;s:17:\"NWACHUKU, Chuke E\";i:14;s:14:\"BLACK, Henry R\";i:15;s:18:\"CUSHMAN, William C\";i:16;s:14:\"DAVIS, Barry R\";i:17;s:15:\"SIMPSON, Lara M\";i:18;s:19:\"ALDERMAN, Michael H\";i:19;s:15:\"ATLAS, Steven A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"HPRTDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Hypertension (Dallas, Tex. 1979)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Hypertension (Dallas Tex., 1979)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:23:\"359-361,374-384 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0194-911X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MESSERLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Franz H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"STAESSEN, Jan A\";i:1;s:13:\"BASILE, Jan N\";i:2;s:18:\"CUYJET, Aloysius B\";i:3;s:13:\"DART, Richard\";i:4;s:18:\"FELICETTA, James V\";i:5;s:16:\"GRIMM, Richard H\";i:6;s:18:\"HAYWOOD, L. Julian\";i:7;s:16:\"JAFRI, Syed Z. A\";i:8;s:19:\"PROSCHAN, Michael A\";i:9;s:13:\"THADANI, Udho\";i:10;s:15:\"WHELTON, Paul K\";i:11;s:18:\"LEENEN, Frans H. H\";i:12;s:17:\"WRIGHT, Jackson T\";i:13;s:17:\"NWACHUKU, Chuke E\";i:14;s:14:\"BLACK, Henry R\";i:15;s:18:\"CUSHMAN, William C\";i:16;s:14:\"DAVIS, Barry R\";i:17;s:15:\"SIMPSON, Lara M\";i:18;s:19:\"ALDERMAN, Michael H\";i:19;s:15:\"ATLAS, Steven A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"HPRTDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:32:\"Hypertension (Dallas, Tex. 1979)\";s:9:\"\u0000*\u0000stitle\";s:32:\"Hypertension (Dallas Tex., 1979)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:0:\"\";s:8:\"\u0000*\u0000epage\";s:0:\"\";s:8:\"\u0000*\u0000pages\";s:23:\"359-361,374-384 [14 p.]\";s:7:\"\u0000*\u0000issn\";s:9:\"0194-911X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"MESSERLI\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Franz H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:15:\"STAESSEN, Jan A\";i:1;s:13:\"BASILE, Jan N\";i:2;s:18:\"CUYJET, Aloysius B\";i:3;s:13:\"DART, Richard\";i:4;s:18:\"FELICETTA, James V\";i:5;s:16:\"GRIMM, Richard H\";i:6;s:18:\"HAYWOOD, L. Julian\";i:7;s:16:\"JAFRI, Syed Z. A\";i:8;s:19:\"PROSCHAN, Michael A\";i:9;s:13:\"THADANI, Udho\";i:10;s:15:\"WHELTON, Paul K\";i:11;s:18:\"LEENEN, Frans H. H\";i:12;s:17:\"WRIGHT, Jackson T\";i:13;s:17:\"NWACHUKU, Chuke E\";i:14;s:14:\"BLACK, Henry R\";i:15;s:18:\"CUSHMAN, William C\";i:16;s:14:\"DAVIS, Barry R\";i:17;s:15:\"SIMPSON, Lara M\";i:18;s:19:\"ALDERMAN, Michael H\";i:19;s:15:\"ATLAS, Steven A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"HPRTDN\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:237:\"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:10:\"Lippincott\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
